Fresenius Medical Care (NYSE:FMS) Upgraded by StockNews.com to Strong-Buy Rating

Fresenius Medical Care (NYSE:FMS) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “strong-buy” rating in a report released on Wednesday.

FMS has been the topic of several other research reports. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Truist Financial increased their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th.

Fresenius Medical Care Stock Performance

Shares of FMS traded down $0.03 during mid-day trading on Wednesday, reaching $24.54. The company had a trading volume of 149,980 shares, compared to its average volume of 237,273. The stock has a market capitalization of $14.40 billion, a P/E ratio of 20.28, a PEG ratio of 0.82 and a beta of 0.93. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $25.25. The stock has a 50 day moving average of $23.29 and a two-hundred day moving average of $21.30. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.42 by $0.03. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.36 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. During the same quarter in the prior year, the firm posted $0.31 EPS. On average, analysts expect that Fresenius Medical Care will post 1.53 earnings per share for the current year.

Institutional Investors Weigh In On Fresenius Medical Care

Institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in shares of Fresenius Medical Care by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock worth $28,000 after buying an additional 806 shares in the last quarter. Allworth Financial LP lifted its stake in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Fresenius Medical Care during the 3rd quarter worth approximately $38,000. GAMMA Investing LLC grew its position in shares of Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after purchasing an additional 1,675 shares in the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in Fresenius Medical Care during the third quarter worth approximately $112,000. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.